Chong Kin Liam

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Yi‐Long Wu, Caicun Zhou, Chong Kin Liam et al. · Annals of Oncology · 2015 · 726 citations

Medicine, Phase Iii, Pathology +7

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 249 citations

Oncology, Met Amplification, Medicine +10

Lung Cancer Screening in Asia: An Expert Consensus Report

David Lam, Chong Kin Liam, Sita Andarini et al. · Journal of Thoracic Oncology · 2023 · 119 citations · Full text

Attitudes and knowledge of newly diagnosed tuberculosis patients regarding the disease, and factors affecting treatment compliance.

Chong Kin Liam, Kuan‐Hon Lim, Catherine Mee‐Ming WONG et al. · PubMed · 1999 · 113 citations